Trial Profile
A 7-day multicenter randomized double-blind, double-dummy parallel group trial to assess the safety and efficacy of 400 mg lumiracoxib once daily versus 500 mg naproxen twice daily in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2008
Price :
$35
*
At a glance
- Drugs Lumiracoxib (Primary) ; Naproxen
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- 01 Nov 2008 Results were reported in the International Journal of Clinical Practice.
- 19 Oct 2006 Status change
- 14 Nov 2005 New trial record.